Biomerica, Inc.

NasdaqCM:BMRA Stock Report

Market Cap: US$5.0m

Biomerica Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Biomerica.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth16.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Analysis Article • Apr 04

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Biomerica, Inc.'s...

Recent updates

Analysis Article • Dec 20

Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Aug 31

Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 04

We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 29

Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test

Biomerica (NASDAQ:BMRA) on Thursday said its Aware Breast Self Exam device and its EZ Detect test for colorectal cancer were now being sold on Amazon.com (AMZN) and fulfilled by Amazon. BMRA's Aware is an at-home device to increase sensitivity in breast self examinations, while the EZ Detect is a 2-minute, at-home test which detects early warnings signs of colorectal cancer. Aware was available on Amazon.com for $19.97, while EZ Detect was priced at $11.98, BMRA said in a statement. Despite the news, Biomerica (BMRA) stock was 1.3% lower at $3.87 in morning trading. BMRA in July said the Aware device would be sold by Walmart (WMT).
Seeking Alpha • Sep 09

Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now

Summary Biomerica is one to keep a close eye on for the future. A lack of earnings momentum and bottom line fundamentals has us sitting on the sidelines. BMRA has upcoming inflection points with its InFoods and H. pylori segments. There are inherent risks in investing in small-cap equities and unprofitable medtech names. This must be considered heavily. We rate BMRA a hold. Investment Summary Biomerica, Inc. (BMRA) is one to watch for the future as it continues to work on unlocking long-term value. BMRA's intense focus on R&D and reinvestment of income back into the company has the probability to garner strong returns if the company can convert its upcoming InFoods and H. pylori pipeline. Despite this, bottom-line fundamentals are weak, and we have wound back speculative positioning to names such as BMRA instead towards cash-generating companies. We have a very close eye on BMRA nevertheless. Rate hold. Risks to Investment Thesis There are many risks investing in small cap equities and unprofitable medtech companies. Volatility can be high and often greater than traditional segments of the market. Investors should also realize that fundamentals can become disconnected from market activity and that being neutral, our investment thesis is subject to upside and downside risks. Corporate Overview Given the stock is lightly covered here on Seeking Alpha, we'll quickly put some flesh on the BMRA skeleton. Firstly, it's a relatively mature company that's been around since 1971, first known as Nuclear Medical Systems, Inc. Today, BMRA has 2 subsidiaries, used for manufacturing and distribution respectively. The company also has ~250 current customers contributing income to its diagnostic business. The split is 32% foreign distributors, 4% domestic distributors, with the remainder (66%) distributed between numerous markets from medical schools to pharma companies to physician's offices. BMRA's diagnostic assay menu contains various test kits that can perform anything from blood analysis, urine, nasal or faecal analysis and for various food intolerances. It sells these in 2 markets primarily - to clinical labs and at the point of care, namely, physicians' offices and drug stores such as Walgreens. Assets to Key Optics On In that note, BMRA is a play on products used at point of care (''POC'') in diagnostics and therapeutics (POC being home care, physician office and hospitals/labs). Specifically, investors gain exposure to diagnostic guided therapy products to treat gastrointestinal ("GI"), in particular, irritable bowel syndrome ("IBS") and irritable bowel disease ("IBD"). Its InFoods IBS offering is a tailored treatment approach that examines a patient's immuno-reactivity to different foods. It then seeks out specific foods from a patient's diet for removal, to alleviate symptoms. Positive readouts from the IBS Endpoint clinical trial with the Mayo Clinic in FY22 demonstrated InFoods IBS may be used to identify and eliminate specifically identified foods to reduce a patient's IBS symptoms. With that, it was granted 6 patents for the InFoods technology during the 12 months, bringing its total to 12 issued patents. Note that it has more than 100 additional filed patents in review. BMRA also finalized its H. pylori diagnostic test. The test is used to determine if a patient is infected with the H. pylori bacteria. Left untreated, it will often progress to GI symptoms like ulcers and malignancies. It applied for its 510K and is awaiting FDA clearance via the premarket submission. The company's InFoods development pipeline is seen in Exhibit 1. Exhibit 1. InFoods is pushing ahead and continues to be an attractive segment. FDA approval would be a key inflection point for the company and likely result in numerous distribution agreements each with their own economic multiplier. Data: BMRA FY22 Investor Presentation FY22 Earnings Comments The company came in with FY22 sales of $18.9 million (''mm'') a YoY gain of 162.5%. Underscoring the growth was an increase in Covid-19 antigen test volumes. Cost of revenues is high for BMRA, however, gross margin was higher YoY at $3mm and 15.7% of sales, ahead of FY21's 5%. The company also saw a ~200bps headwind at the SG&A line to ~$5.7mm. Meanwhile, operating loss came in at a slightly improved $4.5mm each from a $7.49mm loss the year prior. Moving down the P&L, it bought this down to a net loss of $4.6mm for the year, up from a c.$7.5mm loss the same time last year. In addition, R&D investment was 17% lower at $1.8mm from $2.2mm the year prior, but was c.9.5% of turnover, nonetheless. The decrease was seen as there both the IBS and H. pylori were validated and required a lower capital budget. Note, BMRA continues to print a series of quarterly and annual operating losses and hasn't clipped a net profit in more than 5-years. However, one feature of value is in BMRA's R&D investment, by our estimation. It continues to invest heavily into innovation and topline growth. However, the company is made to expense its R&D investment on the income statement as OPEX under GAAP accounting. We have capitalized this R&D investment in FY22, as seen in Exhibit 2, which adjusts book value up by c. $1.8mm for the period. The resulting adjustments also result in a slight adjustment to earnings, with an adjusted loss per share of $0.21 from the reported $0.36 loss per share for Q2 FY22. Exhibit 2. BMRA asset book (FY22) after adding R&D investment onto the balance sheet Data: HB Insights, BMRA SEC Filings As seen in Exhibit 3, we recalculated the company's return on invested capital on GAAP terms and then once again by adding in the semiannual and annual R&D investment, as in the same process above. The result is a small but noticeable improvement in ROIC, data that may have implications further downstream for the company. Note, there's been a strong correlation between ROIC and enterprise value ("EV") since FY20. Exhibit 3. Despite a small adjustment to invested capital by adding back in R&D investment, the ROIC has shifted higher in recent periods
Seeking Alpha • Aug 29

Biomerica reports FY results

Biomerica press release (NASDAQ:BMRA): FY Revenue of $18.8M (+161.1% Y/Y). Net loss was $4.6 million for fiscal 2022 compared to a net loss of $7.5 million for fiscal 2021.
Seeking Alpha • Jul 14

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Biomerica (NASDAQ:BMRA) stock surged ~28% in Thursday premarket trading after the company said its Aware Breast Self Exam device will now be sold by Walmart (WMT). BMRA said that Walmart will initially begin selling the product online in the U.S. Biomerica (BMRA) also said that it is in the final phase of working with the retail giant to stock and sell the breast self examination device in physical Walmart stores in the U.S. The company is also negotiating with other partners to distribute the device in markets outside of the U.S. "As one of the largest retail corporations in the world, Walmart provides unmatched visibility and distribution for this potentially life-saving product. We look forward to supporting Walmart in the product roll-out, ensuring that as many women as possible have access to this product,” said BMRA CEO Zack Irani.
Analysis Article • Dec 03

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Despite strong share price growth of 66% for Biomerica, Inc. ( NASDAQ:BMRA ) over the last few years, earnings growth...
Analysis Article • Dec 02

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 15

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Biomerica recently reported its fiscal 2021 Q4 results highlighted by key product updates supporting a positive long-term outlook. The company's irritable bowel syndrome "IBS" diagnostic therapy technology platform continues to move towards an FDA approval representing a significant growth opportunity. While the stock has been volatile, we believe upcoming catalysts can drive shares higher through 2022.
Analysis Article • Jun 13

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 04

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Biomerica, Inc.'s...
Analysis Article • Mar 08

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Analysis Article • Feb 10

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. By way of example...
Analysis Article • Jan 15

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Buying shares in the best businesses can build meaningful wealth for you and your family. While not every stock...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomerica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:BMRA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
2/28/20264-4-3-3N/A
11/30/20254-4-3-3N/A
8/31/20255-4-3-3N/A
5/31/20255-5-4-4N/A
2/28/20256-5-4-4N/A
11/30/20246-6-5-5N/A
8/31/20246-6-5-5N/A
5/31/20245-6-5-5N/A
2/29/20245-6-5-5N/A
11/30/20236-6-5-5N/A
8/31/20235-6-6-6N/A
5/31/20235-7-6-5N/A
2/28/202310-7-9-9N/A
11/30/202216-6-5-5N/A
8/31/202219-5-2-2N/A
5/31/202219-5-10N/A
2/28/202215-433N/A
11/30/202111-7-1-1N/A
8/31/20217-7-4-4N/A
5/31/20217-7-6-5N/A
2/28/20219-6-8-8N/A
11/30/20206-5-7-7N/A
8/31/20207-4-6-6N/A
5/31/20207-2-4-4N/A
2/29/20205-3-2-2N/A
11/30/20195-2N/A-2N/A
8/31/20195-2N/A-1N/A
5/31/20195-2N/A-2N/A
2/28/20195-2N/A-2N/A
11/30/20185-2N/A-2N/A
8/31/20185-2N/A-2N/A
5/31/20186-1N/A-1N/A
2/28/20186-1N/A-1N/A
11/30/20176-1N/A-1N/A
8/31/20176-1N/A-1N/A
5/31/20176-1N/A-1N/A
2/28/20176-2N/A0N/A
11/30/20166-2N/A0N/A
8/31/20165-1N/A0N/A
5/31/20165-1N/A0N/A
2/29/201650N/A0N/A
11/30/201550N/A-1N/A
8/31/201550N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BMRA's forecast earnings growth is above the savings rate (3.7%).

Earnings vs Market: Insufficient data to determine if BMRA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if BMRA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if BMRA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if BMRA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BMRA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/06 11:01
End of Day Share Price 2026/08/06 00:00
Earnings2026/02/28
Annual Earnings2025/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biomerica, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation
Andrew D'SilvaB. Riley Securities, Inc.
Kyle BauserColliers Securities